Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment

Table 4 Kaplan meier univariate analysis of overall accumulative survival in 316 hepatocellular carcinoma patients after radiofrequency ablation

Variable	No. of patients	Survival rate (%)					P value
		1-yr	3-yr	5-yr	7-yr	10-yr
Sex							0.570
Male	250	89.8	70.4	53.2	44.8	33.0
Female	66	90.7	72.1	37.8	23.6	-
Age (yr)							0.163
< 60	176	90.3	67.6	48.0	31.7	26.4
≥ 60	140	89.6	75.8	58.0	55.4	25.2
Pathology grade							< 0.001
Well-Moderate differentiated	126	94.4	82.5	64.2	53.0	42.5
Poor-differentiated	78	83.6	51.9	33.1	26.5	16.1
Etiology of cirrhosis							0.474
HBV	231	91.2	72.8	55.1	36.1	21.7
HCV	37	95.8	76.7	57.5	57.5	-
Portal vein hypertension							< 0.001
No	211	94.2	78.5	63.0	51.8	36.2
Yes	103	79.8	53.2	30.2	20.4	10.2
Liver function enzyme							0.489
Normal	229	89.0	73.5	54.4	42.1	30.0
Elevated	87	92.2	64.1	45.6	40.5	-
Child-Pugh classification							< 0.001
A	250	94.1	78.9	60.1	50.5	33.6
B	57	82.5	46.8	25.9	17.2	17.2
C	9	28.6	14.3	0	0	0
Serum AFP (ng/mL)							0.037
Normal	177	88.4	75.1	59.2	53.3	35.4
Abnormal	139	91.8	66	42.1	25.7	22.1
CEUS pre-RFA							< 0.001
No	83	80.1	56.2	37.7	26.1	18.0
Yes	233	93.8	77.1	59.7	54.4	-
Number of tumors							< 0.001
Single	248	90.6	75.3	59.3	46.8	34.5
≥ 2	68	87.6	54.6	27.0	21.6	10.8
Tumor size (cm)							0.178
≤ 3.0	147	94.0	71.6	59.2	49.0	18.4
3.0-5.0	169	86.8	69.8	47.3	36.4	25.2
Risky location							0.668
No	152	91.4	71.5	48.6	41.6	32.7
Yes	164	88.6	70.0	53.1	40.6	27.7
Type of RFA electrodes							<0.001
Umbrella	213	86.8	64.3	45.7	36.7	23.6
Single	103	97.5	94.1	62.7	62.7	-
Primary technical success							0.006
Yes	301	89.9	69.1	51.4	39.6	30.6
No	15	54.5	36.4	18.2	0	0
Number of RFA sessions							0.793
1	256	90.2	70.1	53.4	40.3	31.0
≥ 2	60	89.3	73.4	49.0	42.4	30.3